Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies-Reference-Cited by-同舟云学术

Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies

Published:2020-06-22 Issue:8 Volume:99 Page:1883-1893
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Gao Xiao-Ning,Lin Ji,Wang Li-Jun,Li Fei,Li Hong-Hua,Wang Shu-Hong,Huang Wen-Rong,Gao Chun-Ji,Yu Li,Liu Dai-Hong^ORCID

Funder

National Natural Science Foundation of China

Natural Science Foundation of Beijing Municipality

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-020-04156-6.pdf

Reference35 articles.

1. Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad A, Antin JH, Savani BN, Lazarus HM, Seftel M, Saber W, Marks D, Aljurf M, Norkin M, Wingard JR, Lindemans CA, Boeckh M, Riches ML, Auletta JJ (2016) Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 127(20):2427–2438

2. Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier M, Sorror ML, Goyal S, Ozkok S, Yi J, Sahoo F, Kimball LE, Jerome KR, Marks MA, Boeckh M (2016) Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 3(3):e119–e127

3. Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T (2015) Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan society for hematopoietic cell transplantation transplantation-related complication working group. Biol Blood Marrow Transplant 21(11):2008–2016

4. Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD, Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum (2017) Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 64(1):87–91

5. Boeckh M, Geballe AP (2011) Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 121(5):1673–1680

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation;Blood Science;2024-01

2. Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide;International Journal of Hematology;2023-07-19

3. Epidemiology, treatment patterns, and disease burden of cytomegalovirus in hematopoietic cell transplant recipients in selected countries outside of Europe and North America: A systematic review;Transplant Infectious Disease;2023-06-08

4. CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients;Open Forum Infectious Diseases;2023-03-27

5. Research Progress on Predisposing Factors and Prevention of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation;Advances in Clinical Medicine;2023